Global C-Reactive Protein Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

C-Reactive Protein Market Size

• The global C-reactive protein market size was valued at USD 5.78 billion in 2025and is expected to reach USD 6.33 billion by 2033, at a CAGR of 1.15% during the forecast period
• The market growth is largely fueled by the rising prevalence of cardiovascular diseases, chronic inflammatory disorders, and infectious diseases, along with increasing clinical use of C-Reactive Protein (CRP) testing as a key biomarker for inflammation detection, risk assessment, and disease monitoring, leading to improved diagnostic accuracy in healthcare settings
• Furthermore, growing demand for early disease diagnosis, increasing adoption of routine laboratory and point-of-care CRP testing, and continuous advancements in high-sensitivity CRP (hs-CRP) assays are establishing C-Reactive Protein testing as an essential tool in modern clinical diagnostics. These converging factors are accelerating the uptake of C-Reactive Protein solutions, thereby significantly boosting the industry's growth

C-Reactive Protein Market Analysis

• C-Reactive Protein (CRP) testing solutions, including high-sensitivity CRP (hs-CRP) assays, standard immunoturbidimetric tests, ELISA-based methods, and point-of-care testing kits, are increasingly vital components of modern diagnostic medicine due to their role in detecting inflammation, assessing cardiovascular risk, and monitoring infection and chronic disease progression
• The escalating demand for C-Reactive Protein testing is primarily fueled by the rising burden of cardiovascular diseases, infectious diseases, and chronic inflammatory conditions, along with increasing adoption of routine diagnostic screening and expanding use of CRP as a reliable biomarker in clinical decision-making
• North America dominated the C-reactive protein market with the largest revenue share of approximately 38.9% in 2025, characterized by advanced healthcare infrastructure, high adoption of advanced diagnostic technologies, strong laboratory testing networks, and increasing use of hs-CRP testing for cardiovascular risk assessment, particularly in the U.S.
• Asia-Pacific is expected to be the fastest growing region in the C-Reactive Protein market during the forecast period due to expanding healthcare access, rising awareness of early disease detection, increasing laboratory testing capacity, and growing prevalence of chronic and infectious diseases across emerging economies
• The Reagents segment dominated the largest market revenue share of 58.3% in 2025, driven by continuous and recurring demand in diagnostic laboratories

Report Scope and C-Reactive Protein Market Segmentation

C-Reactive Protein Market Trends

“Advancements in High-Sensitivity Diagnostics and Point-of-Care Testing”

• A significant and accelerating trend in the global C-Reactive Protein (CRP) market is the increasing adoption of high-sensitivity CRP (hs-CRP) assays and point-of-care (POC) testing solutions that enable rapid detection of inflammation and infection markers. This shift is improving clinical decision-making speed in emergency care, chronic disease monitoring, and preventive healthcare
• For instance, high-sensitivity CRP testing is increasingly being used in cardiovascular risk assessment to identify low-grade systemic inflammation linked to atherosclerosis. In several cardiology clinics across the U.S. and Europe, hs-CRP testing is routinely integrated into preventive screening programs for patients at risk of coronary artery disease
• Another important development is the expansion of point-of-care CRP testing devices in primary care and urgent care settings. These rapid diagnostic tools allow clinicians to differentiate between bacterial and viral infections within minutes, reducing unnecessary antibiotic prescriptions. For instance, in countries such as the United Kingdom and Sweden, POC CRP testing has been widely adopted in general practice to support antimicrobial stewardship programs
• In addition, automation in laboratory diagnostics is enhancing CRP testing efficiency and accuracy. Fully automated immunoassay analyzers are being increasingly deployed in hospital laboratories to handle high test volumes with improved turnaround times and reduced manual error
• There is also growing integration of CRP testing in chronic disease management, particularly for conditions such as rheumatoid arthritis, inflammatory bowel disease, and lupus, where monitoring inflammation levels is essential for treatment optimization
• Globally, rising awareness of early disease detection and preventive healthcare is contributing to increased demand for CRP testing across both developed and emerging healthcare systems

C-Reactive Protein Market Dynamics

Driver

“Rising Prevalence of Chronic Inflammatory and Infectious Diseases”

• The increasing global burden of chronic inflammatory disorders and infectious diseases is a major driver of the C-Reactive Protein market. Conditions such as cardiovascular disease, rheumatoid arthritis, diabetes, and respiratory infections are contributing to higher utilization of CRP testing in both diagnostic and monitoring applications
• For instance, in recent years, hospitals across Asia-Pacific and North America have reported increased use of CRP testing for early identification of sepsis in emergency departments, where rapid inflammation markers are critical for timely intervention and patient survival
• Growing awareness among physicians about the role of CRP as a reliable biomarker for systemic inflammation is further strengthening its adoption in routine clinical practice. CRP testing is increasingly included in standard diagnostic panels for fever of unknown origin and suspected infections
• Expanding healthcare access and improving laboratory infrastructure in emerging economies are also supporting higher test volumes. Countries in Asia-Pacific and Latin America are witnessing increased adoption of routine inflammatory marker testing due to rising healthcare investments and expanding hospital networks
• In addition, preventive healthcare trends and increasing focus on early disease detection are encouraging routine CRP screening in high-risk populations, particularly for cardiovascular risk stratification

Restraint/Challenge

“Limited Disease Specificity and Variability in Clinical Interpretation”

• A key challenge in the C-Reactive Protein market is the limited specificity of CRP as a biomarker, as elevated levels indicate the presence of inflammation but do not identify the exact underlying cause. This can complicate clinical interpretation and may require additional diagnostic testing
• For instance, elevated CRP levels may be observed in infections, autoimmune disorders, trauma, or chronic diseases, making it difficult for clinicians to rely solely on CRP for definitive diagnosis without complementary tests
• Another challenge is variability in CRP levels due to patient-specific factors such as age, obesity, smoking status, and comorbid conditions, which can influence test accuracy and interpretation in clinical setting
• In some healthcare systems, inconsistent standardization of testing methods and reference ranges can also lead to variability in results between laboratories, affecting diagnostic reliability
• In addition, over-reliance on CRP testing without clinical correlation may lead to unnecessary follow-up tests or treatment decisions, increasing healthcare costs and resource utilization
• Addressing these challenges will require improved diagnostic guidelines, integration of CRP with other biomarkers, and enhanced clinician training to ensure accurate interpretation and effective clinical use

C-Reactive Protein Market Scope

The market is segmented on the basis of assay type, detection range, disease, analysis mode, end-user, and product type.

• By Assay Type

On the basis of assay type, the C-Reactive Protein Testing market is segmented into Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, and Others. The Immunoturbidimetric Assay segment dominated the largest market revenue share of 41.8% in 2025, driven by its widespread use in routine clinical diagnostics due to high automation compatibility and cost efficiency. It is extensively used in hospital laboratories for large-scale inflammatory screening. Rapid turnaround time enhances its suitability for emergency diagnostics. Strong integration with automated analyzers improves laboratory workflow efficiency. High accuracy in quantifying CRP levels supports clinical decision-making. Increasing prevalence of infectious and inflammatory diseases boosts test demand. Expanding diagnostic infrastructure in emerging economies further strengthens adoption. Rising hospital-based testing volumes continue to support segment leadership. Favorable reimbursement policies in developed regions enhance usage. Growing demand for routine health checkups contributes to market dominance. Continuous technological improvements in assay platforms reinforce reliability.

The Chemiluminescence Immunoassay (CLIA) segment is expected to witness the fastest CAGR of 23.6% from 2026 to 2033, driven by superior analytical sensitivity and precision in detecting low CRP concentrations. It is increasingly preferred in advanced diagnostic laboratories and research settings. Rising demand for high-sensitivity CRP (hs-CRP) testing supports adoption. Growing cardiovascular risk screening programs boost utilization. Automation-friendly platforms enhance laboratory efficiency and throughput. Increasing prevalence of chronic inflammatory and autoimmune diseases fuels demand. Expanding use in precision medicine strengthens clinical relevance. Technological advancements in immunoassay systems improve accuracy. Rising healthcare expenditure supports adoption of advanced diagnostic methods. Growing awareness of early disease detection promotes usage. Strong clinical validation of CLIA-based tests enhances physician confidence. Continuous innovation in diagnostic instrumentation drives rapid segment expansion.

• By Detection Range

On the basis of detection range, the C-Reactive Protein Testing market is segmented into hs-CRP, Conventional CRP, and cCRP. The Conventional CRP segment accounted for the largest market revenue share of 47.2% in 2025, driven by its extensive use in diagnosing acute infections and inflammatory conditions. It is widely adopted as a standard diagnostic marker in hospital laboratories. High affordability and simplicity support large-scale usage. Strong physician preference for routine inflammation assessment reinforces dominance. Increasing hospital admissions for infectious diseases boosts demand. Expanding diagnostic accessibility in developing regions supports growth. Integration into routine pathology panels enhances utilization. Growing awareness of inflammatory biomarkers strengthens testing rates. High test accuracy in detecting acute conditions supports reliability. Increasing emergency care diagnostics further drives adoption. Established clinical guidelines favor its widespread use. Continuous demand from routine health screenings reinforces market leadership.

The hs-CRP segment is expected to witness the fastest CAGR of 24.9% from 2026 to 2033, driven by rising demand for cardiovascular risk prediction and preventive healthcare. It enables detection of low-grade inflammation linked to heart diseases. Increasing prevalence of cardiovascular disorders globally supports adoption. Growing focus on early disease detection and risk stratification boosts utilization. Rising use in routine health checkups enhances demand. Expanding awareness of preventive diagnostics strengthens adoption rates. Clinical guidelines increasingly recommend hs-CRP testing for risk assessment. Technological advancements improve test sensitivity and accuracy. Growing geriatric population increases screening demand. Expanding wellness programs and insurance-based health checks support growth. Rising integration in outpatient diagnostic services boosts market penetration. Continuous innovation in high-sensitivity testing platforms accelerates segment expansion.

• By Disease

On the basis of disease, the C-Reactive Protein Testing market is segmented into Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Syphilis, Inflammatory Diseases, Diabetes, and Others. The Cardiovascular Diseases segment dominated the largest market revenue share of 29.5% in 2025, driven by strong clinical reliance on CRP as a biomarker for inflammation and cardiac risk prediction. Rising global burden of heart diseases significantly boosts testing demand. High adoption of hs-CRP testing for preventive screening supports growth. Increasing elderly population contributes to higher disease prevalence. Strong integration in cardiovascular risk assessment protocols reinforces dominance. Expanding awareness of heart health drives routine testing. Growing hospital-based diagnostic volume supports segment leadership. Increasing lifestyle-related risk factors elevate demand for early detection. Clinical guidelines strongly support CRP testing in cardiac evaluation. Advancements in preventive cardiology enhance adoption. Rising healthcare expenditure improves access to diagnostics. Continuous monitoring needs in chronic heart patients further strengthen market position.

The Rheumatoid Arthritis segment is expected to witness the fastest CAGR of 25.3% from 2026 to 2033, driven by increasing prevalence of autoimmune disorders globally. CRP testing plays a key role in monitoring disease activity and treatment response. Rising awareness of early arthritis diagnosis boosts testing demand. Increasing use of biologics requires continuous inflammation monitoring. Expanding rheumatology clinics supports diagnostic uptake. Growing focus on personalized treatment strategies enhances adoption. Rising incidence of autoimmune diseases accelerates demand. Improved access to diagnostic services supports early detection. Increasing clinical trials in autoimmune therapies strengthen usage. Growing patient awareness of chronic inflammatory diseases boosts testing rates. Expanding healthcare infrastructure improves accessibility. Continuous research in inflammatory biomarkers enhances clinical importance.

• By Analysis Mode

On the basis of analysis mode, the C-Reactive Protein Testing market is segmented into Serum, Plasma, and Blood. The Serum segment held the largest market revenue share of 52.6% in 2025, driven by its high accuracy, reliability, and widespread use in clinical laboratories. Serum-based testing is considered the gold standard for CRP measurement. Strong compatibility with automated analyzers enhances efficiency. Increasing hospital-based diagnostic testing supports dominance. Growing demand for routine inflammation screening boosts usage. High precision and minimal sample interference improve reliability. Expanding healthcare infrastructure strengthens adoption. Rising chronic disease burden increases testing volume. Integration into standard diagnostic workflows supports growth. Physician preference for serum testing reinforces leadership. Established laboratory protocols favor serum-based assays. Continuous diagnostic demand from outpatient and inpatient care strengthens market position.

The Plasma segment is expected to witness the fastest CAGR of 22.7% from 2026 to 2033, driven by faster processing time and suitability for emergency diagnostics. Increasing adoption in critical care settings supports growth. Rising demand for rapid testing in hospitals boosts utilization. Improved anticoagulant technologies enhance accuracy. Expanding use in point-of-care testing strengthens adoption. Growing preference for time-sensitive diagnostics accelerates demand. Increasing emergency admissions support segment expansion. Technological advancements improve plasma-based assay performance. Rising healthcare digitization supports laboratory efficiency. Expanding diagnostic capacity in developing regions boosts usage. Continuous innovation in sample processing enhances reliability. Strong demand for quick inflammatory assessment drives growth.

• By End-User

On the basis of end-user, the C-Reactive Protein Testing market is segmented into Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others. The Hospitals segment dominated the largest market revenue share of 44.9% in 2025, driven by high patient inflow and advanced diagnostic infrastructure. Hospitals serve as primary centers for inflammatory disease diagnosis. Strong availability of laboratory services supports dominance. Increasing inpatient and emergency cases boosts testing demand. Integration of CRP testing into routine hospital diagnostics enhances utilization. Growing prevalence of infectious and chronic diseases drives demand. Expanding healthcare facilities improve accessibility. Availability of skilled professionals ensures accurate testing. Rising healthcare expenditure strengthens hospital capabilities. Continuous demand for acute care diagnostics supports growth. Strong adoption of automated laboratory systems reinforces leadership. Increasing complex disease management in hospitals further boosts usage.

The Home segment is expected to witness the fastest CAGR of 26.1% from 2026 to 2033, driven by rising adoption of home-based diagnostic kits and point-of-care testing devices. Increasing demand for self-monitoring of chronic conditions supports growth. Growing prevalence of lifestyle diseases boosts home testing adoption. Technological advancements enable portable CRP testing devices. Rising telehealth integration encourages remote diagnostics. Expanding awareness of preventive healthcare supports demand. Increasing convenience of at-home testing strengthens adoption. Growing elderly population supports home healthcare usage. Improved affordability of testing kits boosts penetration. Rising digital health platforms enhance accessibility. Continuous innovation in wearable and portable diagnostics drives expansion. Strong patient preference for home convenience accelerates growth.

• By Product Type

On the basis of product type, the C-Reactive Protein Testing market is segmented into Kits and Reagents. The Reagents segment dominated the largest market revenue share of 58.3% in 2025, driven by continuous and recurring demand in diagnostic laboratories. Reagents are essential for routine CRP testing workflows. High test volumes in hospitals and labs support dominance. Increasing burden of infectious and inflammatory diseases boosts consumption. Strong integration with automated analyzers enhances efficiency. Expanding diagnostic networks reinforce usage. Growing healthcare infrastructure supports continuous demand. Rising frequency of routine testing increases reagent consumption. Cost-effective bulk usage strengthens market leadership. Established laboratory protocols favor reagent-based testing. Increasing chronic disease monitoring supports steady demand. Continuous diagnostic activity ensures sustained market growth.

The Kits segment is expected to witness the fastest CAGR of 24.4% from 2026 to 2033, driven by rising demand for ready-to-use diagnostic solutions. Increasing adoption of point-of-care testing supports growth. Growing preference for rapid diagnostic results boosts usage. Expanding home healthcare trends enhance demand. Rising awareness of self-testing kits supports adoption. Technological advancements improve kit accuracy and usability. Increasing small laboratory and clinic adoption strengthens growth. Convenience and reduced preparation time enhance preference. Expanding telehealth integration supports remote diagnostics. Growing demand for portable testing solutions boosts usage. Continuous innovation in rapid CRP kits accelerates market expansion. Strong focus on decentralized diagnostics drives segment growth.

C-Reactive Protein Market Regional Analysis

• North America dominated the C-reactive protein market with the largest revenue share of approximately 38.9% in 2025, characterized by advanced healthcare infrastructure, high adoption of advanced diagnostic technologies, strong laboratory testing networks, and increasing use of hs-CRP testing for cardiovascular risk assessment, particularly in the U.S.
• Clinicians and healthcare providers in the region highly value rapid, accurate inflammatory biomarker testing, particularly for early detection and monitoring of cardiovascular diseases, autoimmune disorders, and infectious conditions, supporting timely clinical decision-making
• This strong market position is further supported by well-established diagnostic laboratory systems, high healthcare expenditure, widespread adoption of preventive screening practices, and continuous innovation in clinical biochemistry testing, making North America a leading hub for C-Reactive Protein diagnostics

U.S. C-Reactive Protein Market Insight

The U.S. C-reactive protein market captured the largest revenue share in 2025 within North America, driven by extensive use of hs-CRP testing in cardiovascular risk assessment and growing integration of biomarker-based diagnostics in routine clinical practice. Increasing focus on preventive healthcare and chronic disease monitoring is further accelerating demand. Advanced laboratory infrastructure and strong adoption of precision diagnostics continue to support market growth.

Europe C-Reactive Protein Market Insight

The Europe C-reactive protein market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of inflammatory and chronic diseases, strong public healthcare systems, and growing adoption of routine biomarker testing. Expanding clinical laboratory networks and preventive screening programs are further supporting market expansion across the region.

U.K. C-Reactive Protein Market Insight

The U.K. C-Reactive Protein market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing use of CRP testing in primary care settings, rising focus on cardiovascular risk management, and expanding diagnostic laboratory services. Growing emphasis on early disease detection is further supporting market adoption.

Germany C-Reactive Protein Market Insight

The Germany C-Reactive Protein market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced diagnostic infrastructure, strong clinical laboratory networks, and increasing use of inflammatory biomarkers in disease monitoring. Germany’s emphasis on evidence-based medicine is further supporting widespread adoption of CRP testing.

Asia-Pacific C-Reactive Protein Market Insight

The Asia-Pacific C-reactive protein market is poised to grow at the fastest CAGR during the forecast period, due to expanding healthcare access, rising awareness of early disease detection, increasing laboratory testing capacity, and growing prevalence of chronic and infectious diseases across emerging economies. Improvements in diagnostic infrastructure are significantly accelerating regional market growth.

Japan C-Reactive Protein Market Insight

The Japan C-reactive protein market is gaining momentum due to advanced healthcare systems, high diagnostic accuracy standards, and increasing use of CRP testing in routine health check-ups. Strong emphasis on preventive healthcare and early detection of chronic diseases supports steady market growth.

China C-Reactive Protein Market Insight

The China C-reactive protein market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to expanding healthcare infrastructure, increasing adoption of diagnostic testing, rising chronic disease burden, and growing availability of advanced laboratory services. Expanding hospital networks and improving access to clinical diagnostics are key factors driving market growth in China.

C-Reactive Protein Market Share

The C-Reactive Protein industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers AG (Germany)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Beckman Coulter (U.S.)
• QuidelOrtho Corporation (U.S.)
• Randox Laboratories Ltd. (U.K.)
• Becton, Dickinson and Company (U.S.)
• Sysmex Corporation (Japan)
• Mindray Medical International (China)
• Horiba Ltd. (Japan)
• Sekisui Diagnostics (Japan)
• Ortho Clinical Diagnostics (U.S.)
• Trinity Biotech plc (Ireland)
• Fujirebio (Japan)
• DiaSorin S.p.A. (Italy)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Hologic, Inc. (U.S.)

Latest Developments in Global C-Reactive Protein Market

• In December 2022, Siemens Healthineers received regulatory clearance for its CardioPhase hs-CRP test, enabling more precise detection of systemic inflammation and supporting early prediction of cardiovascular disease risk in clinical settings
• In November 2022, ProciseDx (USA) received FDA clearance for its point-of-care CRP test system, capable of delivering quantitative CRP results in under 5 minutes, significantly improving rapid infection and inflammation diagnosis in emergency care settings
• In January 2022, LumiraDx obtained CE Mark approval for its portable CRP test, a microfluidic immunoassay system designed for rapid, quantitative measurement of inflammation markers at the point of care, supporting decentralized diagnostic testing in Europe
• In February 2023, Qlife Holding AB launched the Egoo CRP test in Sweden, a consumer-accessible diagnostic platform designed for at-home and near-patient inflammation monitoring, marking progress toward self-testing in CRP diagnostics
• In March 2022, Novo Integrated Sciences and Boditech Med signed a Memorandum of Understanding (MoU) to expand distribution of Boditech’s CRP-based IVD solutions in North America, strengthening global commercialization of point-of-care inflammation testing technologies
• In July 2025, Siemens Healthineers received My Green Lab ACT Ecolabel certification for over 150 immunoassay reagents, including CRP-related assays, reflecting growing industry emphasis on sustainable diagnostic manufacturing and environmentally responsible laboratory testing
• In September 2025, HORIBA announced an AI-driven diagnostic partnership with GeodAIsics, integrating hematology and inflammation markers including CRP to improve early sepsis detection and predictive analytics in clinical laboratories

SKU-44791